Resistin is an adipokine that was originally discovered in 2001 by Dr. Mitchell Lazar's group as a link between diabetes and obesity, since then, it has emerged as a potential player in the pathogenesis of colorectal cancer (CRC) [1]. Here, RETN is linked to diabetes mellitus.